We are live on
!
Find out more
ACA
Avoro Capital Advisors Portfolio holdings
AUM
$11.1B
1-Year Est. Return
207.82%
This Fund
S&P 500
This Quarter
Est. Return
-3.61%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$6.41B
AUM Growth
-$663M
(-9.4%)
Cap. Flow
-$121M
Cap. Flow
% of AUM
-1.89%
Top 10 Holdings %
Top 10 Hldgs %
73.95%
Holding
40
New
1
Increased
13
Reduced
7
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$260M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$66.3M |
| 3 |
Kymera Therapeutics
KYMR
|
+$47.8M |
| 4 |
MRUS
Merus
MRUS
|
+$38.2M |
| 5 |
ETNB
89bio
ETNB
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$302M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$96.1M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
+$30.1M |
| 4 |
United Therapeutics
UTHR
|
+$29.2M |
| 5 |
Iovance Biotherapeutics
IOVA
|
+$25.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TRML
26
DELISTED
Tourmaline Bio
TRML
| $36.9M | 0.58% |
2,425,000
+202,778
| +9% | +$3.25M |
|
27
Ultragenyx Pharmaceutical
RARE
$1.29B
| $30.1M | 0.47% |
830,000
| – | – |
|
28
Taysha Gene Therapies
TSHA
$1.65B
| $27.8M | 0.43% |
19,999,999
| – | – |
|
29
uniQure
QURE
$2.99B
| $23.1M | 0.36% |
2,175,000
| – | – |
|
30
Monte Rosa Therapeutics
GLUE
$1.11B
| $21.6M | 0.34% |
4,645,548
+300,548
| +7% | +$1.84M |
|
|
AUTL
31
Autolus Therapeutics
AUTL
$503M
| $15.4M | 0.24% |
9,910,642
| – | – |
|
|
SEPN
32
Septerna Inc
SEPN
$1.81B
| $7.74M | 0.12% |
1,337,500
+227,500
| +20% | +$2.6M |
|
|
WHWK
33
Whitehawk Therapeutics
WHWK
$233M
| $5.07M | 0.08% |
2,849,402
| – | – |
|
|
34
BioMarin Pharmaceuticals
BMRN
$12.5B
| – | – |
-1,462,500
| Closed | -$96.1M |
|
35
CG Oncology
CGON
$6.43B
| – | – |
-700,000
| Closed | -$20.1M |
|
|
36
Iovance Biotherapeutics
IOVA
$4.24B
| – | – |
-3,500,000
| Closed | -$25.9M |
|
37
Kura Oncology
KURA
$1.01B
| – | – |
-2,250,000
| Closed | -$19.6M |
|
38
Olema Pharmaceuticals
OLMA
$856M
| – | – |
-1,651,982
| Closed | -$9.63M |
|
39
Rocket Pharmaceuticals
RCKT
$374M
| – | – |
-1,200,000
| Closed | -$15.1M |
|
|
40
Syndax Pharmaceuticals
SNDX
$1.62B
| – | – |
-2,275,000
| Closed | -$30.1M |
|
Similar funds
GI
AIM
BEI
VNIM
MF
MC
GJL
LCAM
Avoro Capital Advisors's Q1 2025 Portfolio in Review
As of Q1 2025, Avoro Capital Advisors held 40 positions worth $6.41B, down 9.4% from $7.07B the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Avoro Capital Advisors's Q1 2025 filing shows 1 new, 13 increased, 7 reduced and 7 closed positions. Its largest new stake was Centessa Pharmaceuticals: 4,050,000 shares worth $58.2M. The largest sale was Intra-Cellular Therapies Inc., an estimated $302M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Avoro Capital Advisors's largest Q1 2025 buy was Centessa Pharmaceuticals: 4,050,000 shares worth $58.2M.
- Avoro Capital Advisors added most to Blueprint Medicines in Q1 2025, an estimated $260M increase.
- Avoro Capital Advisors's biggest Q1 2025 reduction was Intra-Cellular Therapies Inc., cutting an estimated $302M.
- Avoro Capital Advisors fully exited BioMarin Pharmaceuticals in Q1 2025, selling an estimated $96.1M.
- Avoro Capital Advisors's ten largest holdings make up 74% of its $6.41B portfolio in Q1 2025.
- Avoro Capital Advisors opened 1 new position and closed 7 in Q1 2025.
- Avoro Capital Advisors's portfolio value fell 9.4% quarter-over-quarter to $6.41B.
Based on Avoro Capital Advisors's 13F filing for Q1 2025, filed 15 May 2025.